SCTX Scribe Therapeutics Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Sep 2, 2026SCTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
SCTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | SCTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | -0.3 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | SCTX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 0.6 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Sep 2, 2026 | $-2.62 | $-3.03 | 13.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Revenue | $2M | $5M | |
| R&D Expense | $9M | $14M | |
| SG&A Expense | $2M | $3M | |
| Operating Expenses | $11M | $17M | |
| Operating Income | $-9M | $-12M | |
| Other Non-op | $383.0K | $880.0K | |
| Pretax Income | $-6M | $-11M | |
| Income Tax | $212.0K | $-712.0K | |
| Net Income | $-6M | $-10M | |
| EPS (Basic) | $-2.62 | $-4.08 | |
| EPS (Diluted) | $-2.62 | $-4.08 | |
| Shares (Basic) | 2,475,898 | 2,429,130 | |
| Shares (Diluted) | 2,475,898 | 2,429,130 | |
| EBITDA | $-9M | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Cash & Equivalents | $36M | · | |
| Short-term Investments | $7M | · | |
| Prepaid Expense | $989.0K | · | |
| Current Assets | $45M | · | |
| PP&E (Net) | $6M | · | |
| PP&E (Gross) | $18M | · | |
| Accum. Depreciation | $12M | · | |
| Other Non-current Assets | $4M | · | |
| Total Assets | $58M | · | |
| Accounts Payable | $3M | · | |
| Accrued Liabilities | $2M | · | |
| Current Liabilities | $79M | · | |
| Capital Leases | $4M | · | |
| Other Non-current Liabilities | $8M | · | |
| Total Liabilities | $102M | · | |
| Common Stock | $14.0K | · | |
| Paid-in Capital | $17M | · | |
| Retained Earnings | $-182M | · | |
| AOCI | $-2.0K | · | |
| Stockholders' Equity | $-165M | · | |
| Liabilities + Equity | $58M | · | |
| Shares Outstanding | 2,485,234 | · |
Profitability
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Operating Margin | -489.8% | · | |
| Net Margin | -337.7% | · | |
| Pretax Margin | -326.6% | · | |
| EBITDA Margin | -489.8% | · | |
| ROA | -22.4% | · | |
| ROE | 7.9% | · | |
| ROIC | 5.9% | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Current Ratio | 0.6 | · | |
| Quick Ratio | 0.5 | · |
Efficiency
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Asset Turnover | 0.1 | · |
Per Share
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Book Value / Share | $-66.33 | · | |
| Revenue / Share | $0.77 | · | |
| Cash / Share | $14.32 | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC, Avoro Ventures LLC, Aghazadeh Behzad | July 30, 2026 | 16.37% | Initial filing | Passive investment | SEC |
| ELI LILLY & Co | July 30, 2026 | 7.30% | Initial filing | Passive investment | SEC |
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VIII LLC | July 29, 2026 | 7.20% | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 8 insiders · 3 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Benjamin L. Oakes | President, CEO | July 23, 2026 A | · | 0 | 0 | $0 |
| David Parrot | Chief Financial Officer | July 23, 2026 A | 1,333 | 2 | 0 | $39,990 |
| Svetlana Lucas | Chief Business Officer | July 23, 2026 A | 3,000 | 1 | 0 | $45,000 |
| GORDON CARL L | Director | July 27, 2026 C | 1,348,825 | 1 | 0 | $15,000,000 |
| James Dean Watson | Director | July 23, 2026 A | · | 0 | 0 | $0 |
| Joshua Bleharski | Director | July 23, 2026 A | · | 0 | 0 | $0 |
| Jennifer A Doudna | 10% owner | July 27, 2026 C | 603,547 | 0 | 0 | $0 |
| Brett Staahl | 10% owner | July 23, 2026 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
SCTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-09-30Mean target $57.00 +239.5%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.